drugset / Trial / NCT00921167
A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
Phase 2
Completed
32 enrolled
Clinical Research Center for Solid Tumor, Korea
Seoul National University Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of bevacizumab plus irinotecan for the patients with recurrent anaplastic astrocytoma or with recurrent glioblastoma multiforme
Timeline
- Start
- 2009-06
- Primary completion
- 2012-06
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Irinotecan | Small molecule | 125 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 340 mg/m2 | — |